Enorama Pharma AB (publ)

Stockholm Stock Exchange ERMA.ST

Enorama Pharma AB (publ) Revenue for the year ending December 31, 2023: USD 134.03 K

Enorama Pharma AB (publ) Revenue is USD 134.03 K for the year ending December 31, 2023, a -79.50% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Enorama Pharma AB (publ) Revenue for the year ending December 31, 2022 was USD 653.89 K, a -46.18% change year over year.
Enorama Pharma AB (publ) Revenue for the year ending December 31, 2021 was USD 1.22 M, a 367.16% change year over year.
Enorama Pharma AB (publ) Revenue for the year ending December 31, 2020 was USD 260.10 K, a -67.88% change year over year.
Enorama Pharma AB (publ) Revenue for the year ending December 31, 2019 was USD 809.78 K, a 36.95% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Stockholm Stock Exchange: ERMA.ST

Enorama Pharma AB (publ)

CEO	Mr. Daniel Schroder
IPO Date	June 10, 2016
Location	Sweden
Headquarters	Södergatan 3
Employees	5
Sector	Health Care
Industries Pharmaceuticals Tobacco

Description

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.

Key trends

Past 5 years